2017-03-22,RedHill Biopharma To Present At The 2017 MAP Conference
2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
2017-03-13,RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference
2017-03-07,RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®
2017-03-06,3 Small Biotechs That Still Have Upside
2017-02-23,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2017-02-23,RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results
2017-02-21,RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-16,RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017
2017-02-13,RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-06,RedHill Biopharma To Present At The BIO CEO & Investor Conference
2017-01-12,RedHill Biopharma Provides 2017 Semi-Annual Business Update
2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
2017-01-10,RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2017-01-09,RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium
2017-01-09,RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management
2017-01-06,RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
2017-01-05,RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON
2017-01-04,RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium
2017-01-03,RedHill Biopharma Announces Exercise Of Underwriters' Option
2017-01-03,RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal®
2016-12-28,RedHill Biopharma To Present At The Biotech Showcase 2017
2016-12-27,RedHill Biopharma Announces Closing Of Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants And Partial Exercise Of The Option Of Underwriters
2016-12-21,RedHill Biopharma Prices Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants 
2016-12-20,RedHill Biopharma Announces Proposed Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants
2016-12-19,RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIVA® For Multiple Myeloma
2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
2016-12-05,RedHill Biopharma To Present At The Jefferies Microbiome Summit
2016-11-21,RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-16,RedHill Biopharma To Present At The German Equity Forum 2016
2016-11-14,RedHill Biopharma Reports 2016 Third Quarter Financial Results
2016-11-10,RedHill Biopharma Reports Positive FDA Type B Meeting On RHB-105 For H. Pylori Infection Ahead Of Confirmatory Phase III Study
2016-11-07,RedHill Biopharma To Host Third Quarter 2016 Financial Results Conference Call On November 14, 2016
2016-11-07,RedHill Biopharma To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA® And Expected Timing Of Top-Line Results
2016-11-02,RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
2016-11-01,RedHill Biopharma To Host Investor Conference Call Today At 18:00 EDT Following Announcement Of Proposed Public Offering Of Its American Depository Shares
2016-11-01,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2016-10-31,RedHill Biopharma To Present At The BIO-Europe 2016 Conference
2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
2016-10-13,RedHill Biopharma To Present At The BIO Investor Forum 2016
2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
2016-10-05,RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA™ In Hepatocellular Carcinoma At The Medical University Of South Carolina
2016-09-27,RedHill Biopharma To Present At The BioNetwork West 2016 Partnering Summit
2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
2016-09-12,RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
2016-09-08,RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center
2016-09-01,RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference
2016-08-31,RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
2016-08-19,One Small Pharma Stock Has Big Potential
2016-08-11,RedHill Biopharma Provides 2016 Semi-Annual R&D Update
2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,RedHill Biopharma Reports 2016 Second Quarter Financial Results
2016-07-21,RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2016-07-19,RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016
2016-07-13,RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment
2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-20,RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D
2016-06-15,RedHill Biopharma To Present At JMP Securities Life Sciences Conference
2016-05-31,RedHill Biopharma To Present At The 2016 BIO International Convention
2016-05-30,RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference
2016-05-04,RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
2016-04-25,RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit
2016-04-20,RedHill Biopharma Reports 2016 First Quarter Financial Results
2016-04-19,RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases
2016-04-18,RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection
2016-04-13,RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016
2016-04-11,RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome
2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
2016-03-28,RedHill Biopharma To Present At Bio-Europe Spring 2016 Conference
2016-03-10,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA™ In Cholangiocarcinoma Cancer
2016-03-09,RedHill Biopharma To Present At The 28th Annual ROTH Conference
2016-03-08,RedHill Biopharma Reports Successful Final Results Of Phase III Study With RHB-105 For H. Pylori Infection
2016-03-01,RedHill Biopharma Provides 2016 R&D Update
2016-02-25,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2016-02-25,RedHill Biopharma Reports 2015 Fourth Quarter And Full-Year Financial Results
2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
2016-02-18,RedHill Biopharma To Host 2015 Fourth Quarter And Year-End Financial Results Conference Call On February 25, 2016
2016-02-17,RedHill Biopharma Appoints Dr. June S. Almenoff And Ms. Theresa M. Stevens To Advisory Board
2016-02-11,RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 Mg And Submission To FDA Of IBS-D Phase II Study Protocol
2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
2016-02-09,RedHill Biopharma Issues Letter To Shareholders
2016-02-08,RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute For Oncology Drug RP101
2016-02-02,RedHill Biopharma To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-05,RedHill Biopharma To Present At Biotech Showcase 2016
2015-12-30,RedHill Biopharma Announces Appointment Of Micha Ben Chorin As Chief Financial Officer
2015-12-15,RedHill Biopharma Announces Appointment Of Rick D. Scruggs To Board Of Directors
2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-11-30,RedHill Biopharma Announces Passing Of Board Member Alicia Rotbard
2015-11-12,RedHill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09,RedHill Biopharma Reports Results For The Third Quarter Of 2015
2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
2015-10-29,RedHill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
2015-10-28,RedHill Biopharma To Present At The BIO-Europe 2015 Conference
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-22,RedHill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
2015-10-22,RedHill Biopharma Announces Planned Management Changes
2015-10-22,RedHill Biopharma Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA(TM) (ABC294640) Prostate Cancer Research
2015-10-19,RedHill Biopharma To Present At The BioNetwork West Partnering Summit
2015-10-14,RedHill Biopharma Provides Update On BEKINDA(TM) Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D
2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
2015-09-09,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
2015-09-08,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
2015-09-02,RedHill Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,RedHill Biopharma Announces Last Patient Visit In The Phase I Study With YELIVA(TM) (ABC294640) For Advanced Solid Tumors
2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
2015-08-24,Ratings Changes Today
2015-08-24,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer
2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
2015-07-29,RedHill Biopharma Reports Results For The Second Quarter Of 2015
2015-07-27,RedHill Biopharma Provides Update On RHB-106 Program Partnered With Salix Pharmaceuticals
2015-07-23,RedHill Biopharma To Host Second Quarter 2015 Financial Results Conference Call On July 29, 2015
2015-07-22,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-07-16,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Announces Size Of Proposed Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Extends Option Agreement For Phase II-Stage Pancreatic Cancer Drug RP101
2015-07-14,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
2015-06-29,RedHill Biopharma Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma
2015-06-19,Redhill Biopharma (RDHL) Is Weak On High Volume Today
2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
2015-06-16,RedHill Biopharma To Present At The 2015 BIO International Convention
2015-06-15,RedHill Biopharma To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection
2015-06-15,RedHill Biopharma Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection
2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-06-08,RedHill Biopharma Completes Treatment Of Last Patient With RHB-105 In Phase III Study
2015-06-03,RedHill Biopharma Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results
2015-05-27,RedHill Biopharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,RedHill Biopharma's Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market
2015-05-08,RedHill Biopharma To Present At The BioTrinity 2015 Partnering Conference
2015-05-07,RedHill Biopharma To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study
2015-05-04,Ratings Changes Today
2015-05-04,RedHill Biopharma To Present At The Oppenheimer 16th Annual Israeli Conference
2015-04-30,RedHill Biopharma Reports Results For The First Quarter Of 2015
2015-04-28,RedHill Biopharma To Present At The BioNetwork East 2015 Partnering Conference
2015-04-27,RedHill Biopharma Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection
2015-04-21,RedHill Biopharma To Host First Quarter 2015 Financial Results Conference Call On April 30, 2015
2015-04-16,RedHill Biopharma Receives Notice Of Allowance For Additional U.S. Patent For RHB-105 H. Pylori Bacterial Infection Treatment
2015-03-31,RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
2015-03-23,RedHill Biopharma To Present At The 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
2015-03-03,RedHill Biopharma To Present At VirtualInvestorConferences.com Online Event On March 5, 2015
2015-03-03,RedHill Biopharma To Present At Bio-Europe Spring 2015 International Partnering Conference
2015-03-03,RedHill Biopharma To Present At The 27th Annual ROTH Conference
2015-03-02,Positive Bioavailability Studies Of RedHill's BEKINDA(TM) To Be Presented At The 2015 American Society For Clinical Pharmacology And Therapeutics (ASCPT) Meeting
2015-02-26,RedHill Biopharma Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-19,RedHill Biopharma To Host 2014 Fourth Quarter And Year-End Financial Results Conference Call On February 26, 2015
2015-02-18,RedHill Biopharma Announces Full Exercise Of Underwriters' Over-Allotment Option
2015-02-13,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-02-12,RedHill Biopharma To Present At The Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
2015-02-10,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-02-09,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
2015-01-28,RedHill Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-09,RedHill Biopharma To Present At Biotech Showcase(TM) 2015 Conference In San Francisco
2015-01-05,RedHill Biopharma Business Outlook And Anticipated Key Milestones For 2015
2014-12-31,RedHill Biopharma Announces Acceptance For Review Of BEKINDA(TM) European Marketing Application For Oncology Support
2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
2014-12-17,RedHill Biopharma Announces First Patients Enrolled In The Phase III Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis
2014-12-09,RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application For Oncology Support
2014-12-02,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting
2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
2014-11-10,FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase III H. Pylori Drug RHB-105
2014-11-10,RedHill Biopharma Reports Results For The Third Quarter Of 2014
2014-10-28,RedHill Biopharma To Host Third Quarter 2014 Financial Results Conference Call On November 10, 2014
2014-10-22,RedHill Biopharma To Present At The 20th Annual BIO-Europe International Partnering Conference
2014-10-08,Redhill Biopharma Ramat Gan is Now Oversold (RDHL)
2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
2014-09-16,RedHill Biopharma To Present At The 14th Annual Biotech In Europe Forum For Global Partnering & Investment
2017-03-22,RedHill Biopharma To Present At The 2017 MAP Conference
2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
2017-03-13,RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference
2017-03-07,RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®
2017-03-06,3 Small Biotechs That Still Have Upside
2017-02-23,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2017-02-23,RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results
2017-02-21,RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-16,RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017
2017-02-13,RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-06,RedHill Biopharma To Present At The BIO CEO & Investor Conference
2017-01-12,RedHill Biopharma Provides 2017 Semi-Annual Business Update
2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
2017-01-10,RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2017-01-09,RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium
2017-01-09,RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management
2017-01-06,RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
2017-01-05,RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON
2017-01-04,RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium
2017-01-03,RedHill Biopharma Announces Exercise Of Underwriters' Option
2017-01-03,RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal®
2016-12-28,RedHill Biopharma To Present At The Biotech Showcase 2017
2016-12-27,RedHill Biopharma Announces Closing Of Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants And Partial Exercise Of The Option Of Underwriters
2016-12-21,RedHill Biopharma Prices Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants 
2016-12-20,RedHill Biopharma Announces Proposed Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants
2016-12-19,RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIVA® For Multiple Myeloma
2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
2016-12-05,RedHill Biopharma To Present At The Jefferies Microbiome Summit
2016-11-21,RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-16,RedHill Biopharma To Present At The German Equity Forum 2016
2016-11-14,RedHill Biopharma Reports 2016 Third Quarter Financial Results
2016-11-10,RedHill Biopharma Reports Positive FDA Type B Meeting On RHB-105 For H. Pylori Infection Ahead Of Confirmatory Phase III Study
2016-11-07,RedHill Biopharma To Host Third Quarter 2016 Financial Results Conference Call On November 14, 2016
2016-11-07,RedHill Biopharma To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA® And Expected Timing Of Top-Line Results
2016-11-02,RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
2016-11-01,RedHill Biopharma To Host Investor Conference Call Today At 18:00 EDT Following Announcement Of Proposed Public Offering Of Its American Depository Shares
2016-11-01,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2016-10-31,RedHill Biopharma To Present At The BIO-Europe 2016 Conference
2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
2016-10-13,RedHill Biopharma To Present At The BIO Investor Forum 2016
2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
2016-10-05,RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA™ In Hepatocellular Carcinoma At The Medical University Of South Carolina
2016-09-27,RedHill Biopharma To Present At The BioNetwork West 2016 Partnering Summit
2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
2016-09-12,RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
2016-09-08,RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center
2016-09-01,RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference
2016-08-31,RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
2016-08-19,One Small Pharma Stock Has Big Potential
2016-08-11,RedHill Biopharma Provides 2016 Semi-Annual R&D Update
2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,RedHill Biopharma Reports 2016 Second Quarter Financial Results
2016-07-21,RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2016-07-19,RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016
2016-07-13,RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment
2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-20,RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D
2016-06-15,RedHill Biopharma To Present At JMP Securities Life Sciences Conference
2016-05-31,RedHill Biopharma To Present At The 2016 BIO International Convention
2016-05-30,RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference
2016-05-04,RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
2016-04-25,RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit
2016-04-20,RedHill Biopharma Reports 2016 First Quarter Financial Results
2016-04-19,RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases
2016-04-18,RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection
2016-04-13,RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016
2016-04-11,RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome
2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
2016-03-28,RedHill Biopharma To Present At Bio-Europe Spring 2016 Conference
2016-03-10,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA™ In Cholangiocarcinoma Cancer
2016-03-09,RedHill Biopharma To Present At The 28th Annual ROTH Conference
2016-03-08,RedHill Biopharma Reports Successful Final Results Of Phase III Study With RHB-105 For H. Pylori Infection
2016-03-01,RedHill Biopharma Provides 2016 R&D Update
2016-02-25,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2016-02-25,RedHill Biopharma Reports 2015 Fourth Quarter And Full-Year Financial Results
2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
2016-02-18,RedHill Biopharma To Host 2015 Fourth Quarter And Year-End Financial Results Conference Call On February 25, 2016
2016-02-17,RedHill Biopharma Appoints Dr. June S. Almenoff And Ms. Theresa M. Stevens To Advisory Board
2016-02-11,RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 Mg And Submission To FDA Of IBS-D Phase II Study Protocol
2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
2016-02-09,RedHill Biopharma Issues Letter To Shareholders
2016-02-08,RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute For Oncology Drug RP101
2016-02-02,RedHill Biopharma To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-05,RedHill Biopharma To Present At Biotech Showcase 2016
2015-12-30,RedHill Biopharma Announces Appointment Of Micha Ben Chorin As Chief Financial Officer
2015-12-15,RedHill Biopharma Announces Appointment Of Rick D. Scruggs To Board Of Directors
2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-11-30,RedHill Biopharma Announces Passing Of Board Member Alicia Rotbard
2015-11-12,RedHill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09,RedHill Biopharma Reports Results For The Third Quarter Of 2015
2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
2015-10-29,RedHill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
2015-10-28,RedHill Biopharma To Present At The BIO-Europe 2015 Conference
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-22,RedHill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
2015-10-22,RedHill Biopharma Announces Planned Management Changes
2015-10-22,RedHill Biopharma Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA(TM) (ABC294640) Prostate Cancer Research
2015-10-19,RedHill Biopharma To Present At The BioNetwork West Partnering Summit
2015-10-14,RedHill Biopharma Provides Update On BEKINDA(TM) Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D
2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
2015-09-09,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
2015-09-08,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
2015-09-02,RedHill Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,RedHill Biopharma Announces Last Patient Visit In The Phase I Study With YELIVA(TM) (ABC294640) For Advanced Solid Tumors
2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
2015-08-24,Ratings Changes Today
2015-08-24,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer
2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
2015-07-29,RedHill Biopharma Reports Results For The Second Quarter Of 2015
2015-07-27,RedHill Biopharma Provides Update On RHB-106 Program Partnered With Salix Pharmaceuticals
2015-07-23,RedHill Biopharma To Host Second Quarter 2015 Financial Results Conference Call On July 29, 2015
2015-07-22,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-07-16,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Announces Size Of Proposed Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Extends Option Agreement For Phase II-Stage Pancreatic Cancer Drug RP101
2015-07-14,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
2015-06-29,RedHill Biopharma Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma
2015-06-19,Redhill Biopharma (RDHL) Is Weak On High Volume Today
2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
2015-06-16,RedHill Biopharma To Present At The 2015 BIO International Convention
2015-06-15,RedHill Biopharma To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection
2015-06-15,RedHill Biopharma Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection
2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-06-08,RedHill Biopharma Completes Treatment Of Last Patient With RHB-105 In Phase III Study
2015-06-03,RedHill Biopharma Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results
2015-05-27,RedHill Biopharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,RedHill Biopharma's Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market
2015-05-08,RedHill Biopharma To Present At The BioTrinity 2015 Partnering Conference
2015-05-07,RedHill Biopharma To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study
2015-05-04,Ratings Changes Today
2015-05-04,RedHill Biopharma To Present At The Oppenheimer 16th Annual Israeli Conference
2015-04-30,RedHill Biopharma Reports Results For The First Quarter Of 2015
2015-04-28,RedHill Biopharma To Present At The BioNetwork East 2015 Partnering Conference
2015-04-27,RedHill Biopharma Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection
2015-04-21,RedHill Biopharma To Host First Quarter 2015 Financial Results Conference Call On April 30, 2015
2015-04-16,RedHill Biopharma Receives Notice Of Allowance For Additional U.S. Patent For RHB-105 H. Pylori Bacterial Infection Treatment
2015-03-31,RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
2015-03-23,RedHill Biopharma To Present At The 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
2015-03-03,RedHill Biopharma To Present At VirtualInvestorConferences.com Online Event On March 5, 2015
2015-03-03,RedHill Biopharma To Present At Bio-Europe Spring 2015 International Partnering Conference
2015-03-03,RedHill Biopharma To Present At The 27th Annual ROTH Conference
2015-03-02,Positive Bioavailability Studies Of RedHill's BEKINDA(TM) To Be Presented At The 2015 American Society For Clinical Pharmacology And Therapeutics (ASCPT) Meeting
2015-02-26,RedHill Biopharma Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-19,RedHill Biopharma To Host 2014 Fourth Quarter And Year-End Financial Results Conference Call On February 26, 2015
2015-02-18,RedHill Biopharma Announces Full Exercise Of Underwriters' Over-Allotment Option
2015-02-13,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-02-12,RedHill Biopharma To Present At The Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
2015-02-10,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-02-09,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
2015-01-28,RedHill Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-09,RedHill Biopharma To Present At Biotech Showcase(TM) 2015 Conference In San Francisco
2015-01-05,RedHill Biopharma Business Outlook And Anticipated Key Milestones For 2015
2014-12-31,RedHill Biopharma Announces Acceptance For Review Of BEKINDA(TM) European Marketing Application For Oncology Support
2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
2014-12-17,RedHill Biopharma Announces First Patients Enrolled In The Phase III Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis
2014-12-09,RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application For Oncology Support
2014-12-02,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting
2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
2014-11-10,FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase III H. Pylori Drug RHB-105
2014-11-10,RedHill Biopharma Reports Results For The Third Quarter Of 2014
2014-10-28,RedHill Biopharma To Host Third Quarter 2014 Financial Results Conference Call On November 10, 2014
2014-10-22,RedHill Biopharma To Present At The 20th Annual BIO-Europe International Partnering Conference
2014-10-08,Redhill Biopharma Ramat Gan is Now Oversold (RDHL)
2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
2014-09-16,RedHill Biopharma To Present At The 14th Annual Biotech In Europe Forum For Global Partnering & Investment
2017-03-22,RedHill Biopharma To Present At The 2017 MAP Conference
2017-03-21,RedHill Biopharma Announces First Patient Dosed In The Open-Label Extension Study To The Phase III Study With RHB-104 For Crohn's Disease
2017-03-13,RedHill Biopharma To Present At The BIO-Europe Spring 2017 Conference
2017-03-07,RedHill Biopharma's Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating To Donnatal®
2017-03-06,3 Small Biotechs That Still Have Upside
2017-02-23,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2017-02-23,RedHill Biopharma Reports 2016 Fourth Quarter And Full-Year Financial Results
2017-02-21,RedHill Biopharma Completes Treatment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-16,RedHill Biopharma To Host Fourth Quarter And Full-Year 2016 Financial Results Conference Call On February 23, 2017
2017-02-13,RedHill Biopharma Announces Enrollment Of Last Patient In BEKINDA® Phase III Study For Acute Gastroenteritis
2017-02-06,RedHill Biopharma To Present At The BIO CEO & Investor Conference
2017-01-12,RedHill Biopharma Provides 2017 Semi-Annual Business Update
2017-01-11,RedHill Biopharma Announces QIDP Fast-Track Designation Granted By FDA To RHB-104 For Nontuberculous Mycobacteria Infections
2017-01-10,RedHill Biopharma Announces First Dosing In RHB-105 Supportive PK Studies Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2017-01-09,RedHill Biopharma's RHB-105 Positive Phase III Study Results For H. Pylori Infection Presented At The Innovations In Gastroenterology 2017 Symposium
2017-01-09,RedHill Biopharma Announces Exercise Of Stock Options By Directors And Senior Management
2017-01-06,RedHill Biopharma Announces YELIVA® (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference
2017-01-05,RedHill Biopharma Announces New Research Collaboration With Aarhus University For Oncology Drug MESUPRON
2017-01-04,RedHill Biopharma To Present The Positive Results Of The First Phase III Study With RHB-105 For H. Pylori Infection At The Innovations In Gastroenterology 2017 Symposium
2017-01-03,RedHill Biopharma Announces Exercise Of Underwriters' Option
2017-01-03,RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement With Concordia For GI Drug Donnatal®
2016-12-28,RedHill Biopharma To Present At The Biotech Showcase 2017
2016-12-27,RedHill Biopharma Announces Closing Of Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants And Partial Exercise Of The Option Of Underwriters
2016-12-21,RedHill Biopharma Prices Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants 
2016-12-20,RedHill Biopharma Announces Proposed Concurrent Public Offering And Registered Direct Offering Of Its American Depositary Shares And Warrants
2016-12-19,RedHill Biopharma Announces First Patient Dosed In Phase Ib/II Study With YELIVA® For Multiple Myeloma
2016-12-14,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT® For Migraines With Pharmatronic Co. In South Korea
2016-12-13,RedHill Biopharma Announces Positive And Unanimous DSMB Recommendation For Continuation Of Phase III Study With RHB-104 For Crohn's Disease
2016-12-12,RedHill Biopharma Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis
2016-12-05,RedHill Biopharma To Present At The Jefferies Microbiome Summit
2016-11-21,RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation At The 2016 EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium
2016-11-16,RedHill Biopharma To Present At The German Equity Forum 2016
2016-11-14,RedHill Biopharma Reports 2016 Third Quarter Financial Results
2016-11-10,RedHill Biopharma Reports Positive FDA Type B Meeting On RHB-105 For H. Pylori Infection Ahead Of Confirmatory Phase III Study
2016-11-07,RedHill Biopharma To Host Third Quarter 2016 Financial Results Conference Call On November 14, 2016
2016-11-07,RedHill Biopharma To Present At The Jefferies 2016 London Healthcare Conference
2016-11-03,RedHill Biopharma Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA® And Expected Timing Of Top-Line Results
2016-11-02,RedHill Biopharma Announces Withdrawal Of Public Offering Of Its American Depositary Shares
2016-11-01,RedHill Biopharma To Host Investor Conference Call Today At 18:00 EDT Following Announcement Of Proposed Public Offering Of Its American Depository Shares
2016-11-01,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2016-10-31,RedHill Biopharma To Present At The BIO-Europe 2016 Conference
2016-10-18,RedHill Biopharma Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis
2016-10-13,RedHill Biopharma To Present At The BIO Investor Forum 2016
2016-10-06,RedHill Biopharma To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn's Disease Program Including The Introduction Of An Option For Early Stop For Success In Q2/2017
2016-10-06,RedHill Biopharma Provides Progress Update On RHB-104 Phase III Crohn's Disease Program And Introduces Option For Early Stop For Success In Q2/2017
2016-10-05,RedHill Biopharma Announces Initiation Of Phase II Study With YELIVA™ In Hepatocellular Carcinoma At The Medical University Of South Carolina
2016-09-27,RedHill Biopharma To Present At The BioNetwork West 2016 Partnering Summit
2016-09-21,RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
2016-09-12,RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
2016-09-08,RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center
2016-09-01,RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference
2016-08-31,RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-29,RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis
2016-08-19,One Small Pharma Stock Has Big Potential
2016-08-11,RedHill Biopharma Provides 2016 Semi-Annual R&D Update
2016-08-01,RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis
2016-07-31,5 Small-Cap Biotechs With Big Potential
2016-07-29,5 Small-Cap Biotechs With Big Potential
2016-07-26,RedHill Biopharma Reports 2016 Second Quarter Financial Results
2016-07-21,RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection
2016-07-19,RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016
2016-07-13,RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment
2016-07-05,RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories
2016-06-22,RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-21,RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors
2016-06-20,RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D
2016-06-15,RedHill Biopharma To Present At JMP Securities Life Sciences Conference
2016-05-31,RedHill Biopharma To Present At The 2016 BIO International Convention
2016-05-30,RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference
2016-05-04,RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study
2016-04-25,RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit
2016-04-20,RedHill Biopharma Reports 2016 First Quarter Financial Results
2016-04-19,RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases
2016-04-18,RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection
2016-04-13,RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016
2016-04-11,RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome
2016-03-31,RedHill Biopharma Announces Interim Results From Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential Of RHB-104 In Multiple Sclerosis
2016-03-29,RedHill Biopharma And IntelGenx Announce RIZAPORT™ Commercialization Term Sheet With Grupo JUSTE For Spain And Additional Potential Territories
2016-03-28,RedHill Biopharma To Present At Bio-Europe Spring 2016 Conference
2016-03-10,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of YELIVA™ In Cholangiocarcinoma Cancer
2016-03-09,RedHill Biopharma To Present At The 28th Annual ROTH Conference
2016-03-08,RedHill Biopharma Reports Successful Final Results Of Phase III Study With RHB-105 For H. Pylori Infection
2016-03-01,RedHill Biopharma Provides 2016 R&D Update
2016-02-25,RedHill Biopharma Announces Availability Of Its Annual Report On Form 20-F Through Its Website
2016-02-25,RedHill Biopharma Reports 2015 Fourth Quarter And Full-Year Financial Results
2016-02-18,RedHill Biopharma Announces Notice Of Allowance For U.S. Patent Covering RIZAPORT™ For Migraines
2016-02-18,RedHill Biopharma To Host 2015 Fourth Quarter And Year-End Financial Results Conference Call On February 25, 2016
2016-02-17,RedHill Biopharma Appoints Dr. June S. Almenoff And Ms. Theresa M. Stevens To Advisory Board
2016-02-11,RedHill Biopharma Announces Successful PK Study With BEKINDA™ 12 Mg And Submission To FDA Of IBS-D Phase II Study Protocol
2016-02-10,RedHill Biopharma Receives Notice Of Allowance Of Fifth U.S. Patent Covering RHB-104 Phase III Crohn's Disease Program
2016-02-09,RedHill Biopharma Issues Letter To Shareholders
2016-02-08,RedHill Biopharma Announces Collaboration With Germany's Fraunhofer Institute For Oncology Drug RP101
2016-02-02,RedHill Biopharma To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-05,RedHill Biopharma To Present At Biotech Showcase 2016
2015-12-30,RedHill Biopharma Announces Appointment Of Micha Ben Chorin As Chief Financial Officer
2015-12-15,RedHill Biopharma Announces Appointment Of Rick D. Scruggs To Board Of Directors
2015-11-30,RedHill Biopharma Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-11-30,RedHill Biopharma Announces Passing Of Board Member Alicia Rotbard
2015-11-12,RedHill Biopharma To Present At The Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09,RedHill Biopharma Reports Results For The Third Quarter Of 2015
2015-11-09,RedHill Biopharma And IntelGenx Announce First European Marketing Approval Of RIZAPORT(TM) (RHB-103) For Migraines
2015-10-29,RedHill Biopharma To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
2015-10-28,RedHill Biopharma To Present At The BIO-Europe 2015 Conference
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-26,RedHill Biopharma Announces Positive Top-line Results From YELIVA(TM) (ABC294640) Phase I Study In Advanced Solid Tumors
2015-10-22,RedHill Biopharma To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
2015-10-22,RedHill Biopharma Announces Planned Management Changes
2015-10-22,RedHill Biopharma Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA(TM) (ABC294640) Prostate Cancer Research
2015-10-19,RedHill Biopharma To Present At The BioNetwork West Partnering Summit
2015-10-14,RedHill Biopharma Provides Update On BEKINDA(TM) Ongoing Phase III Study For Gastroenteritis And Announces Planned Phase II Study For IBS-D
2015-09-10,RedHill Biopharma And IntelGenx Announce RIZAPORT(TM) (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
2015-09-09,RedHill Biopharma Announces $2 Million National Cancer Institute Grant for YELIVA(TM) (ABC294640) Phase II Study for Multiple Myeloma
2015-09-08,RedHill Biopharma Announces Standard-of-Care Eradication Data From the RHB-105 Phase III Study Further Supporting the Study's Positive Results
2015-09-02,RedHill Biopharma To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
2015-09-01,RedHill Biopharma Announces Last Patient Visit In The Phase I Study With YELIVA(TM) (ABC294640) For Advanced Solid Tumors
2015-08-27,RedHill Biopharma Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
2015-08-24,Ratings Changes Today
2015-08-24,RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer
2015-08-12,RedHill Biopharma To Present RHB-104 Phase III Crohn's Program At The International Research Symposium On Crohn's Disease
2015-07-29,RedHill Biopharma Reports Results For The Second Quarter Of 2015
2015-07-27,RedHill Biopharma Provides Update On RHB-106 Program Partnered With Salix Pharmaceuticals
2015-07-23,RedHill Biopharma To Host Second Quarter 2015 Financial Results Conference Call On July 29, 2015
2015-07-22,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-07-16,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Announces Size Of Proposed Public Offering Of Its American Depository Shares
2015-07-15,RedHill Biopharma Extends Option Agreement For Phase II-Stage Pancreatic Cancer Drug RP101
2015-07-14,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-07-06,RedHill Biopharma Receives Authorization In Australia And New Zealand For Ongoing Phase III Crohn's Disease Study With RHB-104
2015-07-01,RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering RHB-104 Ongoing Phase III Crohn's Disease Program
2015-06-29,RedHill Biopharma Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma
2015-06-19,Redhill Biopharma (RDHL) Is Weak On High Volume Today
2015-06-16,RedHill Biopharma Announces Acceptance Of Phase III Trial Application In Europe With RHB-104 For Crohn's Disease
2015-06-16,RedHill Biopharma To Present At The 2015 BIO International Convention
2015-06-15,RedHill Biopharma To Host Conference Call Today To Review Positive Phase III Top-Line Results With RHB-105 For H. Pylori Infection
2015-06-15,RedHill Biopharma Successfully Meets Primary Endpoint In Phase III Study Of RHB-105 For H. Pylori Infection
2015-06-09,RedHill Biopharma Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis
2015-06-08,RedHill Biopharma Completes Treatment Of Last Patient With RHB-105 In Phase III Study
2015-06-03,RedHill Biopharma Provides Update On Development Pipeline And Expected Timing For RHB-105 Phase III Top-Line Results
2015-05-27,RedHill Biopharma To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-18,RedHill Biopharma's Investor Webcast Forum Provides Update On The RHB-105 Phase III Program And Potential H. Pylori Eradication Market
2015-05-08,RedHill Biopharma To Present At The BioTrinity 2015 Partnering Conference
2015-05-07,RedHill Biopharma To Host Investor Webcast Forum Following Completion Of RHB-105 Dosing In Phase III Study
2015-05-04,Ratings Changes Today
2015-05-04,RedHill Biopharma To Present At The Oppenheimer 16th Annual Israeli Conference
2015-04-30,RedHill Biopharma Reports Results For The First Quarter Of 2015
2015-04-28,RedHill Biopharma To Present At The BioNetwork East 2015 Partnering Conference
2015-04-27,RedHill Biopharma Announces Completion Of Patient Enrollment In A Phase III Study Of RHB-105 For H. Pylori Infection
2015-04-21,RedHill Biopharma To Host First Quarter 2015 Financial Results Conference Call On April 30, 2015
2015-04-16,RedHill Biopharma Receives Notice Of Allowance For Additional U.S. Patent For RHB-105 H. Pylori Bacterial Infection Treatment
2015-03-31,RedHill Biopharma Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech
2015-03-23,RedHill Biopharma To Present At The 3rd Annual Autoimmune & Inflammation Leaders' Forum 2015
2015-03-03,RedHill Biopharma To Present At VirtualInvestorConferences.com Online Event On March 5, 2015
2015-03-03,RedHill Biopharma To Present At Bio-Europe Spring 2015 International Partnering Conference
2015-03-03,RedHill Biopharma To Present At The 27th Annual ROTH Conference
2015-03-02,Positive Bioavailability Studies Of RedHill's BEKINDA(TM) To Be Presented At The 2015 American Society For Clinical Pharmacology And Therapeutics (ASCPT) Meeting
2015-02-26,RedHill Biopharma Reports 2014 Fourth Quarter And Year-End Financial Results
2015-02-19,RedHill Biopharma To Host 2014 Fourth Quarter And Year-End Financial Results Conference Call On February 26, 2015
2015-02-18,RedHill Biopharma Announces Full Exercise Of Underwriters' Over-Allotment Option
2015-02-13,RedHill Biopharma Announces Closing Of Public Offering Of Its American Depository Shares
2015-02-12,RedHill Biopharma To Present At The Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
2015-02-10,RedHill Biopharma Prices Public Offering Of Its American Depository Shares
2015-02-09,RedHill Biopharma Announces Proposed Public Offering Of Its American Depository Shares
2015-01-29,RedHill Biopharma Provides Update On Progress With RHB-104 Ongoing Phase III Program For Crohn's Disease Following FDA Meeting
2015-01-28,RedHill Biopharma To Present At The 17th Annual BIO CEO & Investor Conference
2015-01-09,RedHill Biopharma To Present At Biotech Showcase(TM) 2015 Conference In San Francisco
2015-01-05,RedHill Biopharma Business Outlook And Anticipated Key Milestones For 2015
2014-12-31,RedHill Biopharma Announces Acceptance For Review Of BEKINDA(TM) European Marketing Application For Oncology Support
2014-12-18,RedHill Biopharma Acquires Technology From University Of Minnesota As Part Of Ongoing RHB-104 Phase III Crohn's Program
2014-12-17,RedHill Biopharma Announces First Patients Enrolled In The Phase III Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis
2014-12-09,RedHill Biopharma Submits BEKINDA(TM) (RHB-102) European Marketing Authorization Application For Oncology Support
2014-12-02,RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting
2014-12-01,RedHill Biopharma And IntelGenx Announce Acceptance For Review Of European Marketing Application For RIZAPORT(TM) For Migraines
2014-11-10,FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase III H. Pylori Drug RHB-105
2014-11-10,RedHill Biopharma Reports Results For The Third Quarter Of 2014
2014-10-28,RedHill Biopharma To Host Third Quarter 2014 Financial Results Conference Call On November 10, 2014
2014-10-22,RedHill Biopharma To Present At The 20th Annual BIO-Europe International Partnering Conference
2014-10-08,Redhill Biopharma Ramat Gan is Now Oversold (RDHL)
2014-10-01,RedHill Biopharma And IntelGenx Submit European Marketing Authorization Application For Migraine Drug RIZAPORT(R) (formerly RHB-103)
2014-09-16,RedHill Biopharma To Present At The 14th Annual Biotech In Europe Forum For Global Partnering & Investment
